Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Infant Bacterial Therapeutics AB (9IB) AI Stock Analysis

DE:9IB

Infant Bacterial Therapeutics AB

(Frankfurt:9IB)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Debt-free balance sheetThe absence of debt reduces interest obligations and refinancing exposure while the company funds clinical development. This provides greater financial flexibility than a leveraged biotech, although it does not remove the need for future financing while programs remain pre-commercial.
Negative Factors
No commercial revenueThe absence of product revenue confirms that the business has not yet reached commercialization and has no established recurring sales base. Future economic value therefore depends on successful clinical development, regulatory approval, and eventual commercialization or partnering.

Infant Bacterial Therapeutics AB (9IB) vs. iShares MSCI Germany ETF (EWG)

-30%-20%-10%0%10%20%30%40%50%DE:9IB+13.79%EWG+5.90%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
Market Cap
EUR 80.75M
Dividend Yield
―
Average Volume (3M)
510
Price to Earnings (P/E)
-10.8
Beta (1Y)
-0.23
Revenue Growth
―
EPS Growth
16.55%
Country
Germany
Employees
6
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Infant Bacterial Therapeutics AB Business Overview & Revenue Model

Company Description

Infant Bacterial Therapeutics AB (publ) operates as a clinical stage pharmaceutical company develops and markets drugs to prevent serious neonatal diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, which is...

Infant Bacterial Therapeutics AB Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:9IB against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
SE:HNSASE:HNSA55NeutralSEK 4.00B-5.00――-3.57%8.84%
SE:XBRANESE:XBRANE53NeutralSEK 291.57M-5.90-11.52%―-38.80%-120.18%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
SE:BINVSE:BINV43NeutralSEK 357.32M-0.73-128.54%―-83.67%-50.29%
SE:EXPRS2SE:EXPRS240UnderperformSEK 36.86M-0.14-104.71%―-2.29%55.71%
SE:IVACCSE:IVACC40UnderperformSEK 263.11M-2.92-34.25%―-0.71%54.16%

* Healthcare Sector Average

Performance Comparison

-50%0%50%DE:9IBSE:HNSASE:BINVSE:XBRANESE:IVACCSE:EXPRS2Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
DE:9IB and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:9IBInfant Bacterial Therapeutics5.940.529.59%
SE:HNSAHansa Biopharma39.348.9429.41%
SE:BINVBioInvent International AB5.43-27.72-83.62%
SE:XBRANEXbrane Biopharma AB14.153.6034.12%
SE:IVACCIntervacc AB0.77-0.19-20.08%
SE:EXPRS2ExpreS2ion Biotech Holding AB0.93-4.99-84.23%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.